Source:http://linkedlifedata.com/resource/pubmed/id/15701710
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2005-4-15
|
pubmed:abstractText |
We evaluated the effects of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), an opener of large conductance Ca(2+)-activated potassium (maxi-K) channels, on normal and stress-exacerbated colonic motility and visceral nociception in the rat. Fecal output was employed as an index of motility. Visceral nociception, in response to intracolonic balloon distension (10-90 mm Hg; 30 s duration), was evaluated using one of three indices: change in blood pressure, abdominal withdrawal, or myoelectrical activity. BMS-223131 (2, 6, or 20 mg/kg i.p.) produced a small but dose-dependent and significant reduction in cumulative 24-h fecal output. Fecal output in response to stress (1-h restraint plus bursts of air to the face) was markedly inhibited by BMS-223131, and moisture content was significantly reduced. With regard to visceral pain, the transient and distention-dependent reduction in arterial pressure in anesthetized animals was inhibited by BMS-223131 in a dose-dependent manner. Distension-induced abdominal withdrawal in conscious rats was also dose-dependently attenuated by BMS-223131. BMS-223131 at a dose of 20 mg/kg markedly attenuated the increase in myoelectrical activity evoked by balloon distention in conscious animals. BMS-223131 was also evaluated in viscerally hypersensitive rats (sensitized as neonates by intracolonic mustard oil) where it produced a robust dose-dependent attenuation of the abdominal withdrawal response. Compared with naive animals, BMS-223131 was more potent in the sensitized animals. Thus, BMS-223131 effectively reduced stress-induced colonic motility and visceral nociception supporting the potential utility of maxi-K channel openers for the treatment of bowel disorders involving dysfunctional motility and visceral sensitivity.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0022-3565
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
313
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
840-7
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:15701710-Animals,
pubmed-meshheading:15701710-Blood Pressure,
pubmed-meshheading:15701710-Colon,
pubmed-meshheading:15701710-Dose-Response Relationship, Drug,
pubmed-meshheading:15701710-Female,
pubmed-meshheading:15701710-Gastrointestinal Motility,
pubmed-meshheading:15701710-Ion Channel Gating,
pubmed-meshheading:15701710-Large-Conductance Calcium-Activated Potassium Channels,
pubmed-meshheading:15701710-Pain Measurement,
pubmed-meshheading:15701710-Potassium Channels, Calcium-Activated,
pubmed-meshheading:15701710-Quinolines,
pubmed-meshheading:15701710-Quinolones,
pubmed-meshheading:15701710-Rats,
pubmed-meshheading:15701710-Rats, Wistar,
pubmed-meshheading:15701710-Stress, Physiological,
pubmed-meshheading:15701710-Viscera
|
pubmed:year |
2005
|
pubmed:articleTitle |
Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress-aggravated colonic motility and visceral nociception.
|
pubmed:affiliation |
Neuroscience Drug Discovery, Pharmaceutical Research Institute, Bristol Myers Squibb Co., Wallingford, CT 06067, USA. siva.digavalli@bms.com
|
pubmed:publicationType |
Journal Article,
Comparative Study
|